42 results about "Cardiac infarction" patented technology

Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.

Compounds of the formula

wherein R₁, R₂, R₃, R₄, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.

This invention relates to ilexin, drug combination of ilexin and its extraction method, which is used to treat CHD, angina pectoris, stroke, cardiac infarction and other cerebral vascular diseases. It uses ethanol for extraction, adds water into the extract, centrifuges to get the sediments and supernatant. Sediments are added 50-95% ethanol for extraction and filtration, the liquid is concentrated, placed and filtrated, and the sediments are dried to get a part of total saponin, the saponin is crystallized by ethanol to get a part of ilexin. The supernatant is enriched and centrifuged for the sediments, which is washed with appropriate water and crystallized by ethanol after dried to get another part of ilxin. Two parts of ilxin are put together and recrystallized for several times to get the pure ilxin, which content can be more than 98.0%.

The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter protein, such as SGLTl, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.

The invention relates to a non-invasive attached telemetering electrocardiographic recording method having an ultra-long record period and an ultra-high storage capacity. By using the method, characteristic values of electrocardiographic waves can be safely, stably and clearly acquired under the natural physiological state of a human body within a long period (more than 15 days), microvolt-level measurements of T-wave alternans can be acquired, and the collection, processing and high-capacity storage of electrocardiographic waves can be completed; and multiple electrocardiographic recording pasters can be used to realize the simultaneous recording of multi-channel body surface electrocardiograms, and a computer data processing and analysis system can complete the data monitoring and analysis, image display, data storage and printing and output of the recorded signals and realize the networking transmission of the electrocardiosignals. The clinical indications of the device include: symptoms related to suspected arrhythmia; determination of arrhythmia property, and completion of reasonably evaluating anti-arrhythmia treatment and monitoring myocardial ischemia; evaluation of anemic heart disease treatment measures; instructions to acute myocardial infarction patients before leaving hospital and during convalescence; and installation, detection and function assessment of sudden cardiac death and heart pacemakers.

An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.

The invention discloses a N, N'-difluoro-substituted-phenyl derivative of 4-methoxyl-1, 3-phenyldiamide, and relative application, while the compound can restrain platelet aggregation activity, to treat the diseases as cardiac infarction, cerebrovascular disorder, pulmonary embolism and atherosclerosis, with antipyretic, analgesia, and antiphlogistic activities.

The invention relates to an imaging method and a device for visualizing coronary heart disease, in particular cardiac infarction lesions, in which at least one image of the heart or heart region comprising at least the myocardium is recorded and reproduced using computed tomography part. The method is characterized in that, by windowing the measured data of the image or the data derived therefrom in the region of the myocardium, regions with insufficient blood supply and/or damage are segmented and displayed in the image in a distinctive manner. In particular, the method according to the invention and the associated device can be used to graphically display the extent of damage after a heart attack.

The invention discloses an immunochromatographic test strip for detecting cardiac infarction and heart failure and a preparation method thereof, and is intended to provide an immunochromatographic test strip that provides detection results accurately determinable and causes few cross reactions. The immunochromatographic test strip comprises a bottom board; a sample pad, a binding pad, a reaction film and an absorbing pad are linked to the bottom board; CRP (C-reactive protein) antibody and chicken IgY labeled by 300 nm immunofluorescence spheres are sprayed to the binding pad, and NT-proBNP antibody labeled by 200 nm immunofluorescence spheres is also sprayed thereto; the reaction film is parallelly provided with a C quality control line, a T1 detection line and a T2 detection line; the C quality control line is coated with goat anti-chicken IgY; the T1 detection line is coated with antigen CRP protein; the T2 detection line is coated with anti-NT-proBNP antibody.

The invention discloses function and application of a Caspase activation and recruitment domain 3 (Card3) gene in a coronary atherosclerotic heart disease. The Card3 gene knockout mice and heart specific Card3 transgenic mice are taken as objects, and a research is carried out on a myocardial infarction model caused by blocking mice heart ramus descendens anterior arteriae coronariae sinistrae. The result proves that compared with WT mice, the cardiac infarction proportion, and the degrees of myocardial hypertrophy and fibrosis of the Card3 gene knockout mice are obviously inhibited, and the cardiac function is obviously improved; the phenotype of the Card3 transgenic mice is contrary to that of the Card3 gene knockout mice. Consequently, the Card3 gene can promote and increase development and progression of the coronary atherosclerotic heart disease, the Card3 can be used as a drug target for screening the drugs for treating the coronary atherosclerotic heart disease, and the inhibitor of the Card3 can be applied to preparation of a drug for treating the coronary atherosclerotic heart disease.

Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)

or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action

wherein each symbol is as defined in the specification.

The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

Methods and apparatuses, including devices and systems, for remote and detection and/or diagnosis of acute myocardial infarction (AMI). In particular, described herein are handheld and adhesive devices having an electrode configuration capable of recording three orthogonal ECG lead signals in an orientation-specific manner, and transmitting these signals to a processor. The processor may be remote or local, and it may automatically or semi-automatically detect AMI, atrial fibrillation or other heart disorders based on the analyses of the deviation of the recorded 3 cardiac signals with respect to previously stored baseline recordings.

The invention discloses a method for detecting myocardial infarction based on wavelet packet features of a short-time HRV signal. The method comprises the steps that first data preprocessing is carried out on a conventional twelve-lead electrocardiogram, R wave locating is carried out, a RR interval is determined, and the HRV signal is obtained; and then wavelet packet decomposition is carried outon the HRV signal to obtain wavelet packet coefficients, then the wavelet packet coefficients are subjected to wavelet packet feature extraction, and finally, the extracted wavelet packet features are normalized for classification and recognition. The method can be applied to the detection of myocardial infarction, effective detection can be performed in a short period of time without adding newdetection equipment, and the method is simple, convenient, easy to operate and high in prediction efficiency.